Bausch Health Companies (BHC) Income from Continuing Operations (2009 - 2026)
Bausch Health Companies (BHC) posted Income from Continuing Operations of 260000000.0 for Q2 2026, up 118.17% sequentially from 1431000000.0 in Q1 2026, and up 103.12% YoY from 128000000.0 in Q2 2025.
Bausch Health Companies (BHC) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Income from Continuing Operations for 18 years, with the latest figure at 260000000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 103.12% year-over-year to 260000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1093000000.0 (down 2377.08% YoY) and the FY2025 annual result came in at 120000000.0, up 266.67% from the prior year.
- Income from Continuing Operations grew to 260000000.0 in Q2 2026 per BHC's latest filing, from 1431000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 403000000.0 in Q3 2022 and troughed at 1431000000.0 in Q1 2026.
- A 5-year average of 108111111.11 and a median of 71500000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations surged 12900.0% in 2025, then slumped 1563.95% in 2026.
- Over 5 years, Income from Continuing Operations stood at 410000000.0 in 2022, then surged by 88.54% to 47000000.0 in 2023, then soared by 308.51% to 98000000.0 in 2024, then sank by 205.1% to 103000000.0 in 2025, then surged by 352.43% to 260000000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 260000000.0, 1431000000.0, and 103000000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn | 260.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 260.00 Mn |
| Mar 31, 2026 | -1.43 Bn |
| Dec 31, 2025 | -103.00 Mn |
| Sep 30, 2025 | 181.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Mar 31, 2025 | -86.00 Mn |
| Dec 31, 2024 | 98.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -1.00 Mn |
| Mar 31, 2024 | -77.00 Mn |
| Dec 31, 2023 | -47.00 Mn |
| Sep 30, 2023 | -382.00 Mn |
| Jun 30, 2023 | 27.00 Mn |
| Mar 31, 2023 | -209.00 Mn |
| Dec 31, 2022 | -410.00 Mn |
| Sep 30, 2022 | 403.00 Mn |
| Jun 30, 2022 | -139.00 Mn |
| Mar 31, 2022 | -66.00 Mn |
| Dec 31, 2021 | 72.00 Mn |
| Sep 30, 2021 | 191.00 Mn |